Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
FASEB J
2022 Mar 01;363:e22203. doi: 10.1096/fj.202101815R.
Show Gene links
Show Anatomy links
Lipid mediator n-3 docosapentaenoic acid-derived protectin D1 enhances synaptic inhibition of hippocampal principal neurons by interaction with a G-protein-coupled receptor.
Mikroulis A
,
Ledri M
,
Ruffolo G
,
Palma E
,
Sperk G
,
Dalli J
,
Vezzani A
,
Kokaia M
.
???displayArticle.abstract???
Epilepsy is a severe neurological disease manifested by spontaneous recurrent seizures due to abnormal hyper-synchronization of neuronal activity. Epilepsy affects about 1% of the population and up to 40% of patients experience seizures that are resistant to currently available drugs, thus highlighting an urgent need for novel treatments. In this regard, anti-inflammatory drugs emerged as potential therapeutic candidates. In particular, specific molecules apt to resolve the neuroinflammatory response occurring in acquired epilepsies have been proven to counteract seizures in experimental models, and humans. One candidate investigational molecule has been recently identified as the lipid mediator n-3 docosapentaenoic acid-derived protectin D1 (PD1n-3DPA ) which significantly reduced seizures, cell loss, and cognitive deficit in a mouse model of acquired epilepsy. However, the mechanisms that mediate the PD1n-3DPA effect remain elusive. We here addressed whether PD1n-3DPA has direct effects on neuronal activity independent of its anti-inflammatory action. We incubated, therefore, hippocampal slices with PD1n-3DPA and investigated its effect on excitatory and inhibitory synaptic inputs to the CA1 pyramidal neurons. We demonstrate that inhibitory drive onto the perisomatic region of the pyramidal neurons is increased by PD1n-3DPA , and this effect is mediated by pertussis toxin-sensitive G-protein coupled receptors. Our data indicate that PD1n-3DPA acts directly on inhibitory transmission, most likely at the presynaptic site of inhibitory synapses as also supported by Xenopus oocytes and immunohistochemical experiments. Thus, in addition to its anti-inflammatory effects, PD1n-3DPA anti-seizure and neuroprotective effects may be mediated by its direct action on neuronal excitability by modulating their synaptic inputs.
Cascino,
Advances in the Surgical Management of Epilepsy: Drug-Resistant Focal Epilepsy in the Adult Patient.
2021, Pubmed
Cascino,
Advances in the Surgical Management of Epilepsy: Drug-Resistant Focal Epilepsy in the Adult Patient.
2021,
Pubmed
Conti,
Anomalous levels of Cl- transporters cause a decrease of GABAergic inhibition in human peritumoral epileptic cortex.
2011,
Pubmed
,
Xenbase
Dalli,
Novel n-3 immunoresolvents: structures and actions.
2013,
Pubmed
Dawit,
When Drugs Do Not Work: Alternatives to Antiseizure Medications.
2020,
Pubmed
Devinsky,
Glia and epilepsy: excitability and inflammation.
2013,
Pubmed
Drexel,
Selective Silencing of Hippocampal Parvalbumin Interneurons Induces Development of Recurrent Spontaneous Limbic Seizures in Mice.
2017,
Pubmed
Essrich,
Postsynaptic clustering of major GABAA receptor subtypes requires the gamma 2 subunit and gephyrin.
1998,
Pubmed
Ferdinandusse,
Identification of the peroxisomal beta-oxidation enzymes involved in the biosynthesis of docosahexaenoic acid.
2001,
Pubmed
Frigerio,
n-3 Docosapentaenoic acid-derived protectin D1 promotes resolution of neuroinflammation and arrests epileptogenesis.
2018,
Pubmed
Gobbetti,
Protectin D1n-3 DPA and resolvin D5n-3 DPA are effectors of intestinal protection.
2017,
Pubmed
Jinno,
Neuronal diversity in GABAergic long-range projections from the hippocampus.
2007,
Pubmed
Jonas,
Quantal components of unitary EPSCs at the mossy fibre synapse on CA3 pyramidal cells of rat hippocampus.
1993,
Pubmed
Khayenko,
Targeting GABAAR-Associated Proteins: New Modulators, Labels and Concepts.
2019,
Pubmed
Klausberger,
Neuronal diversity and temporal dynamics: the unity of hippocampal circuit operations.
2008,
Pubmed
Markram,
Redistribution of synaptic efficacy between neocortical pyramidal neurons.
1996,
Pubmed
Palma,
Expression of human epileptic temporal lobe neurotransmitter receptors in Xenopus oocytes: An innovative approach to study epilepsy.
2002,
Pubmed
,
Xenbase
Pardridge,
CSF, blood-brain barrier, and brain drug delivery.
2016,
Pubmed
Pirker,
GABA(A) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain.
2000,
Pubmed
Roseti,
GABAA currents are decreased by IL-1β in epileptogenic tissue of patients with temporal lobe epilepsy: implications for ictogenesis.
2015,
Pubmed
,
Xenbase
Ruffolo,
A novel GABAergic dysfunction in human Dravet syndrome.
2018,
Pubmed
,
Xenbase
Schindelin,
Fiji: an open-source platform for biological-image analysis.
2012,
Pubmed
Serhan,
New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration.
2018,
Pubmed
Sperk,
GABA(A) receptor subunits in the rat hippocampus I: immunocytochemical distribution of 13 subunits.
1997,
Pubmed
Taha,
Selective reduction of excitatory hippocampal sharp waves by docosahexaenoic acid and its methyl ester analog ex-vivo.
2013,
Pubmed
van Vliet,
Review: Neuroinflammatory pathways as treatment targets and biomarker candidates in epilepsy: emerging evidence from preclinical and clinical studies.
2018,
Pubmed
Vezzani,
Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy.
2019,
Pubmed
Vezzani,
Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability.
2015,
Pubmed
Weissberg,
Albumin induces excitatory synaptogenesis through astrocytic TGF-β/ALK5 signaling in a model of acquired epilepsy following blood-brain barrier dysfunction.
2015,
Pubmed
Xiao,
Polyunsaturated fatty acids modify mouse hippocampal neuronal excitability during excitotoxic or convulsant stimulation.
1999,
Pubmed